Two thoughtful articles on the #radiopharmaceutical space written by Melanie Senior and Rachel Nuwer of Nature Magazine Biotechnology. They highlight the growing interest of pharma companies and investors in #radioligand #therapy, while also exploring critical industry challenges. These include the need for reliable, high-quality supplies of medical isotopes and the identification of new targets across more tumor indications. Additionally, emerging pre-clinical and clinical data for both Pb212 and Ac225 show improved patient survival rates and effective targeting of low-expression cancer cells, particularly when radioactive isotopes are combined with checkpoint inhibitors. These takeaways echo many of the themes and discussions we heard at the recent Society of Nuclear Medicine and Molecular Imaging (SNMMI) congress in Toronto. The alpha precursor #Pb212 is poised to be a game-changer in terms of efficacy and patient safety, with ARTBIO’s proprietary technology facilitating its supply and manufacturing routes. With few novel radiopharma targets available, our innovative approach to #alpha radioligand therapy (ART) development stands out and overcomes the challenges of existing #RLTs. Read the Nature articles here: https://lnkd.in/ep_Na-ma and https://lnkd.in/efiKbxgJ Learn more about ARTBIO’s novel approach at www.artbio.com #nuclearmedicine #biotech
Fascinating insights into the #radiopharmaceutical space! The articles by Melanie Senior and Rachel Nuwer shed light on promising advancements and critical challenges in radioligand therapy. ARTBIO's innovative approach with Pb212 sounds particularly promising for improving efficacy and patient safety. Looking forward to seeing more breakthroughs in this field! 🌟 #AlphaRadioligandTherapy #CancerResearch
Senior Client Relationship Manager at InsightAce Analytic Pvt. Ltd.
3moCurrent Scenario in the Radiopharmaceutical Sector: https://www.biospace.com/article/releases/radiopharmaceutical-industry-outlook-growth-trends-and-future-prospects/